Illinois medical device maker Baxter‘s (NYSE:BAX) won European regulatory approval for its VIVIA hemodialysis system, designed for use in multiple settings and therapy regimens.
The VIVIA system, designed to be operated primarily by a patient, is indicated for use in "more frequent, extended duration, short daily or nocturnal home [high-dose] therapy," Baxter said. VIVIA features touch-screen technology, a graphic interface and animations that guide patients through setup, treatment and cleanup.
The VIVIA system also uses wireless communication to connect patients with clinicians via the Sharesource platform, allowing doctors and nurses to remotely monitor home therapy.
The device will 1st become available next year in a limited number of dialysis clinics, with the commercial launch slated for expansion to other European countries in 2015, according to a press release.